Meeting News

Lipid-lowering agents reduce risk for CV events, but not inflammation

January 7, 2019
CHICAGO – Agents that decrease LDL cholesterol levels also reduce the risk for major adverse CV events, though they do not limit inflammation…
Meeting News

Long-term risk assessment increases number of patients eligible for statins

January 4, 2019
CHICAGO – A 30-year risk threshold doubled the number of patients designated as eligible for statin therapy in primary care, according to…
Meeting News

Alirocumab lowers LDL cholesterol in hypercholesterolemia

December 18, 2018
CHICAGO – Alirocumab decreases LDL cholesterol in a “clinically meaningful way” among patients with autosomal dominant…
Meeting News

OSLER-1 trial demonstrates efficacy, safety of evolocumab in hypercholesterolemia

December 17, 2018
CHICAGO – Treatment with evolocumab decreased LDL cholesterol consistently without escalating the rate of adverse events or leading to the…
Meeting News

Cholesterol impacts CV mortality risk in patients with chronic kidney disease

November 27, 2018
CHICAGO — Low serum cholesterol may increase CV mortality risk across chronic kidney disease stages, according to data from a cohort of older…
Meeting News

Many eligible patients do not receive statin therapy

November 27, 2018
CHICAGO — A significant portion of patients identified as candidates for statin therapy according to 2013 ACC/AHA guidelines received the…
Meeting News

Calcium level may yield more accurate risk score in FH patients

November 26, 2018
CHICAGO – Adjusting the Framingham risk score to reflect the atherosclerotic burden for patients with familial hypercholesterolemia may more…